Implications of Cannabis and Cannabinoid Use in COVID-19: Scoping Review

Implicaciones del uso de Cannabis y cannabinoides en el COVID-19: revisión de alcance

ABSTRACT

Objective:

to identify and synthesize studies on the effects of cannabis use and its relation with SARS-CoV-2, as well as the therapeutic possibilities of using cannabinoids in the prevention and treatment of COVID-19.

Methods:

scoping review, in the BVS, PubMed, SCIELO, CINAHL, SCOPUS, Web of Science, MedNar, CAPES and ProQuest databases, with no language restriction and year limitation. Narrative synthesis was performed.

Results:

cannabis use causes changes in the respiratory and vascular system, it reduces the production of cytokines, which affects the users’ immune system, increasing the susceptibility to infection and progression of COVID-19. However, studies have suggested the use of cannabinoids in the prophylaxis and treatment of COVID-19, due to their anti-inflammatory effect.

Conclusions:

the use of inhaled cannabis increases the progression and severity of the infection. On the other hand, the benefits of cannabinoids seem promising to modulate the immune system, but it needs further studies.

Descriptors:
Marijuana Use; Cannabis; Coronavirus Infections; Mental Health; Nursing

RESUMEN

Objetivo:

identificar y sintetizar los estudios sobre los efectos del uso de cannabis y su relación con el SARS-CoV-2, así como las posibilidades terapéuticas de los cannabinoides para la prevención y el tratamiento del COVID-19.

Métodos:

revisión de alcance, sin límite de lenguaje y año, planteada en las bases BVS, PubMed, SCIELO, CINAHL, SCOPUS, Web of Science, MedNar, CAPES y ProQuest y desarrollada como síntesis narrativa.

Resultados:

el consumo de cannabis provoca alteraciones en los sistemas respiratorio y cardiovascular; reduce la producción de citosinas, lo que afecta el sistema inmunológico de los usuarios, aumentando la susceptibilidad a la infección y a la progresión del COVID-19. Sin embargo, algunos estudios sugieren el uso de cannabinoides en la profilaxis y en el tratamiento del COVID-19, debido a su efecto antiinflamatorio.

Conclusiones:

el uso de cannabis inhalado aumenta la progresión y la gravedad de la infección. Por otra parte, los beneficios de los cannabinoides parecen prometedores para modular el sistema inmunitario, aunque se necesitan más estudios sobre el tema.

Descriptores:
Uso de la Marihuana; Cannabis; Infecciones por Coronavirus; Salud Mental; Enfermería

RESUMO

Objetivo:

identificar e sintetizar os estudos sobre os efeitos do uso da cannabis e sua relação com o SARS-CoV-2, bem como as possibilidades terapêuticas da utilização de canabinoides na prevenção e no tratamento da COVID-19.

Métodos:

revisão de escopo, sem limitação de linguagem e ano, nas bases BVS, PubMed, SCIELO, CINAHL, SCOPUS, Web of Science, MedNar, CAPES e ProQuest. Foi realizada síntese narrativa.

Resultados:

o consumo de cannabis provoca alterações no sistema respiratório e vascular; reduz a produção de citocinas, o que afeta o sistema imunológico dos usuários, aumentando a susceptibilidade à infecção e a progressão da COVID-19. No entanto, estudos sugeriram o uso de canabinoides na profilaxia e no tratamento da COVID-19, devido ao seu efeito anti-inflamatório.

Conclusões:

o uso de cannabis inalada aumenta a progressão e a severidade da infecção. Por outro lado, os benefícios dos canabinoides parecem promissores para modular o sistema imunológico, mas necessita de mais estudos.

Descritores:
Uso da Maconha; Cannabis; Infecções por Coronavírus; Saúde Mental; Enfermagem

INTRODUCTION

In 2019, the world was surprised by the first contemporary pandemic, COVID-19 (Coronavirus Disease 2019), caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2), which spread rapidly, causing death of more than 1900000 people(¹). SARS-CoV-2 is part of the Coronaviridae family, which gets its name due to the appearance of a crown when viewed under electron microscopy(²). This coronavirus is responsible for causing respiratory syndrome and effects on other systems, such as the cardiac, renal(³) and central nervous system(⁴). Coronaviruses are known to cause Severe Acute Respiratory Syndromes (SARS) in humans, such as SARS-CoV (2002), in China, and MERS-CoV (Middle East Respiratory Syndrome) (2012), in Saudi Arabia(⁵).

The disease caused by SARS-CoV-2 quickly reached pandemic status, reported by the World Health Organization (WHO) on March 11, 2020(⁶). In this context, a worrying factor is that about 25% of individuals present the infection asymptomatically(⁷), which further contributes to the rapid spread of the disease due to the lack of isolation necessary to contain the transmission(⁸), especially because these cases of asymptomatic infection are more common among young people, a population that least adheres to isolation measures(⁹). On the other hand, the possibility of aggravation of the infection was verified in individuals considered more susceptible and prone to complications, including the older adults and people with clinical and chronic comorbidities (pulmonary, cardiovascular, cerebrovascular and diabetes)(¹⁰).

The use of inhaled Psychoactive Substances (PS) can also favor the susceptibility of the organism of these individuals. Marijuana (Cannabis sativa) is the most consumed illicit PS in the world, since its use has been growing in recent years(¹¹). One of the explanations for the increased use is the levels of THC in plants, which increased from 2% in the 1990s to around 28% nowadays(¹²). In Brazil, the prevalence of users aged 12 to 65 years old is 3.1% - among people living in Brazilian capitals(¹³).

The use of marijuana causes repercussions on the respiratory system, such as dyspnea, cough and sputum production(¹⁴). These events, associated with the respiratory and pulmonary effects resulting from SARS-CoV-2 infection, provide a higher risk of complications of the clinical picture(¹⁵-¹⁶). In addition, the shared use of marijuana cigarettes is also a worrying factor, due to the greater possibility of contagion(¹⁷). Regarding the use of cannabis and its components for therapeutic purposes, information is still controversial as to its effectiveness. However, authors(¹⁸-¹⁹) raised the hypothesis that marijuana users demonstrated a systemic reduction in the production of cytokines, speculating that cannabidiol (CBD) as a potential inhibitor of the rapid elevation of cytokines during SARS-CoV-2 infection(²⁰-²¹). Given the context of the pandemic, studies that report adverse effects of marijuana and studies that report the therapeutic effect of CBD, and considering the lack of reviews that group these two views, a review that summarizes the main findings is important.

OBJECTIVE

To identify and synthesize studies on the effects of cannabis use and its relationship with SARS-CoV-2, as well as the therapeutic possibilities of using cannabinoids in the prevention and treatment of COVID-19.

METHODS

This study was designed as a scoping review(²²) which aims to map the main concepts that support a given area of knowledge; to examine the extent, scope and nature of the investigation, summarize and disseminate research data, and identify gaps in existing research. In addition to the items for systematic reviews and meta-analyses (PRISMA)(²³), the specific PRISMA extension for scope reviews (PRISMA-ScR) was also followed, which is ideal for thoroughly describing the decision process of research, considering the method used(²⁴).

The PCC strategy (acronym for P: Population = cannabis users; C: Concept = effects of cannabis; and C: Context = COVID-19) was used to elaborate the guiding question of the study: “What are the knowledge available in the literature on the relationship between the effects of cannabis use and COVID-19?”.

Search strategy

The search strategy was conducted in three stages. The first stage of the research was carried out in PubMed and the BVS (including the BDENF, LILACS, MEDLINE, PAHO-IRIS, WHOLIS and MEDCARIB databases) to analyze the words in the title and abstract of the studies in order to increase the sensitivity of the search strategy, using the following keywords: “Cannabis Smoking”, “SARS Virus”, “COVID-19”. In the second stage, the studies were identified through a search strategy adapted to each electronic database: BVS, SCIELO, PubMed, CINAHL, SCOPUS and Web of Science), with the objective of identifying studies on the subject; and gray literature in the MedNar, CAPES and ProQuest theses and dissertations catalog with the objective of identifying guidelines, manuals, dissertations and theses. A search strategy was developed with the following terms in PubMed, adapted for the other databases: (Cannabis OR “Marijuana Smoking” OR “Marijuana Abuse” OR “Marijuana Use”) AND (“COVID19” OR “Corona Virus Disease 2019” OR Coronavirus OR “SARS Virus”).

In the third stage, a search was carried out in the references of the selected articles to find studies that were not collected by the search strategy. After collecting all references, duplicate studies were excluded using Mendeley® software. Searches in electronic information sources were carried out from July 2, 2020 to January 5, 2021.

Eligibility criteria

The inclusion criteria were quasi-experimental studies, randomized clinical trials, cohort, case-control, cross-sectional, letters to the editor or opinion, qualitative studies, review, guidelines, manuals, dissertations and theses that addressed the effects of the use of cannabis and its relationship with COVID-19, its use as a means of preventing infection, and the use of cannabinoids in cases of infection. There was no restriction of language or year of publication.

The instrument “The System for the Unified Management, Assessment and Review of Information” (SUMARI)(²⁵) was used for the methodological evaluation of the articles included in the study by two independent evaluators.

Study selection

The selection of studies was carried out in two phases by the authors of this article. Initially, the titles and abstracts were independently examined in order to verify whether the studies addressed the study’s guiding question and met the established inclusion and exclusion criteria. In phase 2, the same reviewers independently read the full text of all selected articles, excluding studies that did not meet the inclusion criteria. Any disagreement, whether in the first or second phase, was resolved through discussion and agreement between the authors. In case of lack of consensus, a third reviewer was involved for the final decision.

Thus, they were sorted through the following process: title reading; abstract framed in the inclusion and exclusion criteria; exclusion of articles that did not answer the research question and, finally, definitive selection of those eligible for full reading.

Data collection process and results synthesis

From each article included in the analysis, the authors extracted the following information for descriptive synthesis: location (country), year of publication, study design and outcomes (results).

Subsequently, and independently, the extracted data were verified and changes were made, if necessary. Then, they carried out the quality assessment of the studies using the SUMARI software, through a critical evaluation checklist for experimental studies, expert opinion and review studies by the Joanna Briggs Institute (JBI)(²²) . Opinion articles and editorials were evaluated using the critical evaluation checklist for opinion studies(²⁶). The cutoff points were established through methodological evaluation checklists for experimental studies, expert opinion and review studies with questions that scored scores from 1 to 10. Articles that scored between 1 and 4 were classified as of poor methodological quality; articles with scores between 5 and 7, of moderate quality and those with a score >7, of high quality.

RESULTS

A total of 803 studies were found, among which 16 were duplicated, leaving 787 studies. Of these, 790 were excluded for not meeting the eligibility criteria. Thus, 13 studies were included. Figure 1 shows the flowchart of the selection process of the articles in this research - PRISMA flow chart.

Figure 1
Flowchart of the study selection process

Characteristics of the studies

All included studies were written in English, with seven studies conducted in the United States, two in Italy, two in Canada, one in South Africa and one in Iran. Eight studies were opinion, two considered experimental, two review studies, and one quasi-experimental. In Chart 1, the descriptive characteristics of the studies are summarized.

Chart 1
Characteristics of the included studies, according to title, year of publication, country, design, outcomes and methodological quality, Brazil, 2020 (N=13)

Title	Year/Country	Design/objective	Outcomes of studies on the effects of cannabis use and its relationship with SARS-COV2 and the therapeutic possibilities of cannabinoids in the prevention and treatment of COVID-19	Methodological quality
Cannabis in the Time of Coronavirus Disease 2019: The Yin and Yang of the Endocannabinoid System in Immunocompetence(16)	2020 USA	Opinion article Objective: To assess whether Phytocannabinoids can be useful or harmful to immune competence in the context of the current COVID-19 pandemic.	• The chronic use of inhaled cannabis can increase coughing, sputum production, wheezing, reduced lung function, and can cause respiratory illnesses. These changes reduce the effectiveness of the response to infection, increasing the risk of rapid progression to hypoxia; • Cannabis users showed systemic reduction in cytokine production; • The endogenous cannabinoid signaling system (ECS) mediates several immunosuppressive effects, including inhibition of immune cell proliferation, migration and antibody production, induction of apoptosis, and suppression of cytokines; • CBD has been perceived as a potential treatment for COVID-19 due to its anti-inflammatory effects.	High
Cannabinoids and the Coronavirus(20)	2020 USA	Opinion article Objective: To identify the benefits and risks of cannabinoids with regard to Covid-19.	• SARS-CoV-2 triggers excessive production of cytokines, resulting in hyperinflammation. CBD could possibly be part of the treatment, associated with non-steroidal anti-inflammatory drugs and other medications that act on the immune system, with the aim of reducing the overproduction of these substances.	High
Cannabidiol Modulates Cytokine Storm in Acute Respiratory Distress Syndrome Induced by Simulated Viral Infection Using Synthetic RNA(21)	2020 USA	Experimental study with animal model. N=15 mice. Objective: To assess whether CBD can reduce cytokine storm and treat acute respiratory distress syndrome.	• The treatment with CBD reversed the inflammatory indices and partially reestablished the body’s homeostasis; • It reduced the expression of interleukin (IL)-6 and decreased the presence of neutrophils in the lung and blood; • It increased the presence of lymphocytes, reduced the number of neutrophils and monocytes, as well as the level of pro-inflammatory cytokines.	High
Cerebrovascular and neurological dysfunction under the threat of COVID-19: Is there a comorbid role for smoking and vaping?(27)	2020 USA	Review article. N=9 studies Objective: To summarize the possible role of smoking and vaporization in cerebrovascular and neurological dysfunction in patients with COVID-19.	• The use of inhaled cannabis can deteriorate the condition of patients with COVID-19, due to airway inflammation, being a risk factor for the development of neurological disorders, due to the harmful effect on the cerebrovascular system.	Moderate
The potential of Cannabidiol in the COVID-19 pandemic(30)	2020 Italy	Opinion article Objective: To identify effective drugs in the new coronavirus disease 2019 (COVID - 19).	• Cannabis sativa extracts with a high content of cannabinoid (CB) are able to reduce the expression of the two main receptors for the installation of SARS-CoV-2 infection: the angiotensin 2 converting enzyme and the serine protease 2 enzymes; • CBD exerts a wide range of immunomodulatory and anti-inflammatory effects, smoothing the uncontrolled production of cytokines in acute lung injury, acting as a regulator of fibroblast/myofibroblast activation .and improving lung function in recovered patients.	High
Acute inflammation and pathogenesis of SAR-CoV-2 infection: cannabidiol as a potential anti-inflammatory treatment(28)	2020 Canada	Opinion article Objective: To assess Cannabidiol’s potential to attenuate excessive inflammation.	• CBs can suppress immune and inflammatory activation by reducing the production of cytokines, suggesting potential to modulate excessive inflammation; • Cannabis use was associated with a reduction in pro-inflammatory monocytes, a reduction in CD4 and CD8 T lymphocyte cells, in addition to tumor necrosis factor alpha (TNF-α), IL-10 and IL-producing antigen-presenting cells 12, compared to non-cannabis users.	Moderate
Cannabinoid receptor type 2: a possible target in SARS-CoV-2 (CoV-19) infection?(34)	2020 Italy	Opinion article Objective: To assess whether the CB2 receptor can be a therapeutic target in the COVID-19 pandemic emergency.	• Endocannabinoid CB2 receptor stimulation is known to limit the release of pro-inflammatory cytokines, change the macrophage phenotype to the M2 anti-inflammatory type, and enhance the immune modulating properties of cells; • For these reasons, it is hypothesized that the CB2 receptor may be a therapeutic target in cases of COVID-19 infection, playing a role in preventing and/or influencing the development and severity of the disease.	Moderate
Opioids/cannabinoids as potential therapeutic approach in COVID-19 patients(35)	2020 Iran	Opinion article Objective: To assess the use of opioids/cannabinoids in the context of COVID-19.	• CB2 stimulation could control the inflammatory cascade caused by SARS-CoV-2 infection, considering its ability to reduce the exacerbated production of pro-inflammatory cytokines; • Considering this scenario, its use can be very beneficial in the exacerbated containment of the inflammatory response in patients with COVID-19.	High
Cannabis for COVID-19: can cannabinoids quell the cytokine storm?(31)	2020 USA	Opinion article Objective: To assess the potential of the pharmacological immunomodulatory effects of cannabinoids that are constituents of the cannabis plant.	• CBs are effective in suppressing the immune system, having immunoregulatory and anti-inflammatory properties, resulting from the activation of CB1 and CB2 receptors; • ECS mediates immunosuppression through cytokine suppression; inhibition of immune cell proliferation, migration and antibody production, allowing control of viral pathogenesis; • The phytocannabinoids, tetrahydrocannabinol (THC) and CBD, have been shown to reduce the exacerbated production of inflammatory cytokines through their immunoregulatory properties.	High
Letter to the Editor: Possible Drug-Drug Interactions Between Cannabinoids and Candidate COVID-19 Drugs(36)	2020 USA	Opinion article Objective: Early identification of possible interactions between cannabinoids and drugs that can be used to treat COVID-19.	• The interaction of some CBs with certain medications can be extremely serious, potentially causing hepatocellular damage and sedation; • The immunosuppressive effects associated with CBD can trigger a primary and/or secondary infectious condition, resulting in a worse prognosis in patients with COVID-19; • A recent in vitro study showed that CBD can antagonize some effects of dexamethasone, replacing its anti-inflammatory potential, when used concomitantly.	High
Genetic Liability to Cannabis Use Disorder and COVID-19 Hospitalization(29)	2020 USA	Quasi-experimental. Cannabis Use Disorder (N case = 14 080, N control = 343 726) and hospitalization for COVID-19 (N case = 6 492, N population control = 1 012 809). Objective: To identify whether genomic responsibility for cannabis use disorder can contribute to severe presentation of COVID-19.	• The heavy and/or problematic use of cannabis associated with the genetic factor for cannabis use disorder may increase the severity of COVID-19 due to respiratory complications; • The formulation of strategies to reduce heavy cannabis use is recommended to mitigate risks in relation to COVID-19.	High
In search of preventive strategies: novel high-CBD Cannabis sativa extracts modulate ACE2 expression in COVID-19 gateway tissues(32)	2020 Canada	Experimental study. N=23 Objective: To assess whether C. sativa extracts with high CBD content can be used to down-regulate ACE2 expression in COVID-19 target tissues.	• By using artificial 3D human tissue models, it was observed that Cannabis sativa extracts with high content of CBD can decrease the expression of angiotensin-converting enzyme (ACE2) in coronavirus target tissues, suggesting the importance of these extracts in prevention of COVID-19; • These results cannot be extrapolated to the effects of cannabis smoking.	High
Coronavirus Disease-2019 Treatment Strategies Targeting Interleukin-6 Signaling and Herbal Medicine(33)	2021 South Africa	Review article. N=15 studies Objective: To map therapeutic strategies by blocking the cytokine storm	• The search for potential strategies to target IL-6 signaling in the treatment of COVID-19 patients, such as: tocilizumab (decreases cytokine release), IL-6 signaling inhibitors (pacritinib, ruxolitinib and tofacitinib), bone marrow-derived exosomes, and dexamethasone; • Another plausible strategy is the use of natural compounds with the ability to inhibit virus entry into host cells; • Among them is Cannabis sativa, which is a plant known for containing anti-inflammatory compounds such as CB, CBD and terpenes.	Moderate

Studies(¹⁶,²⁷-²⁸) point to evidence that cannabis in the inhaled form causes important changes in the respiratory and in the vascular system, causing damage to the individuals’ brain structure, reduction in the concentration of T CD4, CD8 and cytokines, which may result in inefficient activation of users’ immune systems. Furthermore, the presence of a genetic risk factor for cannabis use disorder is correlated with COVID-19 and an increase in hospitalization cases(²⁹).

On the other hand, researches(¹⁶,²⁰-²¹,³⁰-³⁵) addressed the possibility of using exogenous CB, especially CBD and THC, in the prophylaxis and treatment of COVID-19 through the suppression of immune activation, with an anti -inflammatory and reduced expression of ACE2 in coronavirus target tissues. A study(³⁶) highlights the risk of drug interactions of THC and/or CBD with anti-inflammatory drugs used in the treatment of infection caused by SARS-CoV-2.

DISCUSSION

This study was designed to analyze the literature on the effects of cannabis and its relationship with SARS-CoV-2, in addition to discussing the possibility of using exogenous CB for therapeutic intervention in cases of infection by this virus, as well as in preventing the disease. During the pandemic and the lockdown period, changes were observed in the population’s routine, directly reflected in the mental health of individuals(³⁷), affected by different degrees of mental suffering. Specialists warn of the possibility of worsening PS use patterns, as this is one of the strategies pointed out for coping with mental suffering(³⁸). A study(³⁹) carried out in Canada highlighted that from May to June 2020, the use of marijuana was maintained, but when compared to the period before the pandemic, these rates increased. On the other hand, the literature indicates that in Belgium and the United States of America there was no change in the use of cannabis during the pandemic(⁴⁰-⁴¹).

Regardless of this controversy, the use of cannabis in the inhaled form causes concern when in the context of COVID-19. This PS has harmful consequences for lung health, reducing the effectiveness of the response to infection through airway inflammation, and may increase the risk of rapid progression to hypoxia in cases of SARS-CoV-2 infection(¹⁵,²⁷). Other alterations are chronic inflammation of the lungs and impairment of the vascular system, due to the large increase in THC levels(⁴²). It is noteworthy that SARS-CoV-2 provokes massive recruitment of macrophages and monocytes, but that, in some cases, this immune response is dysfunctional and directly affects the respiratory system, which can be exacerbated in a systemic way(⁴³).

The chronic use of cannabis is related to cardiac events (atrial fibrillation and acute coronary syndromes) and effects on cerebral blood vessels(⁴⁴-⁴⁵). This evidence may be important for more detailed observations in the treatment of these individuals, as SARS-CoV-2 directly affects the myocardium, in addition to causing venous thromboembolism and arterial thrombosis in the neurovascular system(⁴⁶). Other important factors highlighted were that the CB present in cannabis can cause an important drug interaction, pointing to the need for adequate investigation regarding its use during a suspicion of contamination by SARS-CoV-2(³⁶). In addition, attention to the genetic factor that predisposes to cannabis use disorder is necessary, being listed as a risk of increased hospitalization in cases of COVID-19(²⁹). In addition to the systemic changes caused by cannabis use, individuals who use it as a medicinal resource may have an increased risk of contracting the infection due to chronic health conditions, such as cancer and heart disease(²⁹,⁴⁷).

In summary, the act of smoking cannabis can be extremely harmful to individuals infected with the coronavirus, contributing to a negative outcome of the disease. Thus, it is necessary to develop longitudinal studies to assess how cannabis users, in the inhaled form, react to SARS-CoV-2 infection. The extremely important role of guidance, prevention and harm reduction performed by nursing in primary health care services and specialized services is highlighted. Through these approaches, the objective is to alert the population to consequences in relation to the use of inhaled cannabis, since cannabis is the second most used drug worldwide, by about 192 million people(⁴⁸).

The data presented show the need to carry out tracking of the use and abuse of cannabis among individuals who present symptoms of contamination by SARS-CoV-2, as it is essential to mitigate the effects caused by this virus. Subsequently, it would be possible to trace a contamination profile to establish a prognosis for this population. Thus, the nurse has the potential to carry out screening and brief intervention effectively(⁴⁹-⁵⁰), strengthening the role of this professional in mental health care(⁵¹), regardless of the health care sector they act. In addition, nurses who work in specialized services in alcohol and other drugs must identify and intervene in risk situations that favor the infection of people by SARS-CoV-2.

Regarding probable therapeutic uses, both THC and CBD have been mentioned in the literature as having an important function of modulating the immune system, acting in the inhibition of inflammatory cytokines and in the stimulation of anti-inflammatory cytokines(⁵²), confirmed by several studies(¹⁶,²⁰-²¹,³⁰-³³,³⁵). Despite disagreements about the safety of cannabis and CB use, some regulatory agencies have allowed the use of CB-based drugs for the treatment of epilepsy and multiple sclerosis and for the relief of symptoms of chemotherapy, allowing new perspectives for future applications(⁵¹,⁵³).

ECS is known to mediate several immunosuppressive effects, including inhibition of immune cell proliferation, migration and antibody production, and induction of apoptosis and suppression of cytokines (via down-regulation of immunoregulatory genes). This suggests the possibility of using exogenous CB in cases of infection by SARS-CoV-2(¹⁶,²⁸,³⁰-³¹,³³), aiming to reduce the excess of cytokines(²⁰). These findings are in line with the treatment guidelines proposed for COVID-19, with the use of agents that perform immunomodulation to reduce excess cytokines in the inflammatory process(⁴⁶).

The use of CBD may also be a promising agent for patients recovering from COVID-19 due to improved pulmonary function(³⁰). Furthermore, the therapeutic potential in the treatment of cardiovascular pathologies has been considered in the literature(⁵¹). Another resource would be the prevention strategy against the entry of SARS-CoV-2, through the use of mouthwashes containing Cannabis sativa with a high content of CBD(³⁰), which would act by modulating the expression of ACE2 expressed in the oral cavity(³²). Studies(³¹,³³) reinforce the need for further research with a view to confirming the beneficial findings in relation to cannabis, CB and other components that have so far been shown to be promising for the treatment of various pathologies, including COVID-19. However, studies(²¹,³⁵-³⁶) alert to the need for more evidence about the mechanisms of action, drug interaction and use in the treatment of COVID-19.

There was little evidence addressing the use of exogenous CB for therapeutic purposes during and after the individual contracted COVID-19, but with positive indications for the immunomodulatory effect through the activation and inhibition of cytokines(¹⁶,²⁰-²¹,²⁸,³⁰-³⁵). Therefore, it is necessary to develop further research that explores this use, especially in individuals with coronavirus infection. As for the non-therapeutic use of cannabis, among people who contracted COVID-19, studies(¹⁶,²⁷,³⁰) point to the health risks in relation to the potential inflammatory triggering of the vascular and respiratory systems, and in relation to the likely danger of the interaction drug with the components of cannabis(³⁶).

Nursing and other health professionals must be aware of this scenario in order to properly guide the population, ensuring understanding the difference between the indiscriminate use of cannabis and the therapeutic use based on scientific evidence. Thus, it avoids misinterpretations and indiscriminate use of this PS as a resource for the prevention of COVID-19, especially among individuals who did not use it.

Limitations of the study

Some limitations of this study should be considered, such as the lack of evidence regarding the use of cannabis and its substrates in patients who developed COVID-19, pointing out that these factors may have been little observed in robust studies. In addition, there is the methodological design of the studies included in the review, since eight selected studies(¹⁶,²⁰,²⁸,³⁰-³¹,³⁴-³⁶) are opinion articles, which limits the affirmation power of the results in relation to the investigated phenomenon. However, this study type is configured as one of the types of manuscripts recommended for including in a scoping review.

Contributions to the area of Nursing, Health or Public Policy

This review aims to bring a contribution of knowledge about the use of cannabis, inhaled and therapeutically, in the context of the COVID-19 pandemic. Nurses are the backbone of the health system, seeking to provide care centered on the individual regardless of the working environment. Thus, during the COVID-19 pandemic, these professionals will certainly provide care to cannabis users, using an empathetic, welcoming and always attentive approach to the peculiarities of the association between cannabis use and SARS-CoV-2. In addition, the nurse must be aware of respiratory and cardiovascular symptoms, in addition to tracking the use of PS, especially cannabis, in individuals under their care, in order to provide more adequate and comprehensive care, based on the biopsychosocial care model. Therefore, it will contribute to improve the prognosis arising from the infection caused by this virus, aiming to improve the prognosis for COVID-19. This study contributes to the formulation of new health policies acting as an evidence-based literature. In addition, it highlights the current theme of the pandemic and its implications, reinforcing the perspective of damage to the body of individuals in the use/abuse of cannabis. On the other hand, it shows the promising potential of isolated components (exogenous CB) for therapeutic purposes and new treatment possibilities for several pathologies that involve exacerbated activation of the immune system.

We emphasize the need to develop more studies that address and investigate the prognosis of patients with COVID-19 and who use inhaled cannabis, as well as the therapeutic use of exogenous cannabinoids in the prevention and treatment of infection by SARS-CoV- 2, for the regulation and adoption of public policy of its use for these purposes to take place.

CONCLUSION

Individuals who use inhaled cannabis may be more susceptible to infection and progression of SARS-CoV-2, due to the effects resulting from this use, which interfere with various systems of the human body. Furthermore, non-therapeutic use may be a risk factor for the development of neurological disorders in people affected by COVID-19. This highlights the need to carry out interventions aimed at preventing the use and abuse of marijuana, reinforcing the harmful relationship with SARS-CoV-2 infection. In this context, nursing professionals are in a privileged situation, due to the intense contact with the individuals under their care at all levels of health care.

Another important factor is the awareness of health professionals about studies that point to cannabis as a promising immunomodulatory and anti-inflammatory drug, bringing to light the benefits of the active ingredients isolated from the plant, such as CBD and THC, for the treatment of the disease caused by SARS-CoV-2.

REFERENCES

• ¹
  World Health Organization (WHO). Painel do WHO Coronavirus Disease (COVID-19) [Internet]. WHO; 2020[cited 2021 Jan 12]. Available from: https://covid19.who.int/
  » https://covid19.who.int/
• ²
  Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-33. https://doi.org/10.1056/NEJMoa2001017
  » https://doi.org/10.1056/NEJMoa2001017
• ³
  Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62. https://doi.org/10.1016/S0140-6736(20)30566-3
  » https://doi.org/10.1016/S0140-6736(20)30566-3
• ⁴
  Groiss SJ, Balloff C, Elben S, Brandenburger T, Müttel T, Kindgen-Milles D, et al. Prolonged neuropsychological deficits, central nervous system involvement, and brain stem affection after COVID-19-A case series. Front Neurol. 2020;11:574004. https://doi.org/10.3389/fneur.2020.574004
  » https://doi.org/10.3389/fneur.2020.574004
• ⁵
  Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes of pneumonia. Respirology. 2018;23(2):130-137. https://doi.org/10.1111/resp.13196
  » https://doi.org/10.1111/resp.13196
• ⁶
  World Health Organization . WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020 [Internet]. WHO Director General’s speeches. 2020[cited 2020 Sep 12];(Mar):4. Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 .
  » https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020
• ⁷
  Dennison HCR, Baptiste D. Coronavirus Disease (COVID-19): Implications for Cardiovascular and Socially At-risk Populations. J Cardiovasc Nurs. 2020;35(4):318-21. https://doi.org/10.1097/JCN.0000000000000710
  » https://doi.org/10.1097/JCN.0000000000000710
• ⁸
  Wilder-Smith A, Chiew CJ, Lee VJ. Can we contain the COVID-19 outbreak with the same measures as for SARS?. Lancet Infect Dis. 2020;20(5):e102-e107. https://doi.org/10.1016/S1473-3099(20)30129-8
  » https://doi.org/10.1016/S1473-3099(20)30129-8
• ⁹
  Nikolai LA, Meyer CG, Kremsner PG, Velavan TP. Asymptomatic SARS Coronavirus 2 infection: Invisible yet invincible. Int J Infect Dis. 2020;100:112-6. https://doi.org/10.1016/j.ijid.2020.08.076
  » https://doi.org/10.1016/j.ijid.2020.08.076
• ¹⁰
  Dunlop A, Lokuge B, Masters D, Sequeira M, Saul P, Dunlop G, et al. Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic. Harm Reduct J. 2020;17(1):26. https://doi.org/10.1186/s12954-020-00370-7
  » https://doi.org/10.1186/s12954-020-00370-7
• ¹¹
  World Drug Report 2018. Executive summary - Conclusions and Policy Implications [Internet]. Vol. 1, United Nations publication, Sales No. E.18.XI.9; 2018 [cited 2020 Nov 28]. Available from: https://www.unodc.org/wdr2018/prelaunch/WDR18_Booklet_1_EXSUM.pdf
  » https://www.unodc.org/wdr2018/prelaunch/WDR18_Booklet_1_EXSUM.pdf
• ¹²
  Stuyt E. The Problem with the Current High Potency THC Marijuana from the Perspective of an Addiction Psychiatrist. Mo Med [Internet]. 2018 [cited 2020 Nov 28];115(6):482-486. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30643324
  » http://www.ncbi.nlm.nih.gov/pubmed/30643324
• ¹³
  Bastos FIPM, Vasconcellos MTL, De Boni RB, et al. 3rd National Survey on Drug Use by the Brazilian Population [Internet]. Rio de Janeiro: FIOCRUZ/ICICT, 2017[cited 2020 Nov 27]. 528 p. Available from: https://www.arca.fiocruz.br/handle/icict/34614
  » https://www.arca.fiocruz.br/handle/icict/34614
• ¹⁴
  Gracie K, Hancox RJ. Cannabis use disorder and the lungs. Addiction. 2020:add.15075. https://doi.org/10.1111/add.15075
  » https://doi.org/10.1111/add.15075
• ¹⁵
  El Biali M, Broers B, Besson M, Demeules J. Cannabinoids and COVID-19. Med Cannabis Cannabinoids. 2020:1-5. https://doi.org/10.1159/000510799
  » https://doi.org/10.1159/000510799
• ¹⁶
  Sexton M. Cannabis in the Time of Coronavirus Disease 2019: The Yin and Yang of the Endocannabinoid System in Immunocompetence. J Altern Complement Med. 2020;26(6):444-8. https://doi.org/10.1089/acm.2020.0144
  » https://doi.org/10.1089/acm.2020.0144
• ¹⁷
  European Monitoring Centre for Drugs and Drug Addiction. EMCDDA Update on the Implications of COVID-19 for People who use Drugs (PWUD) and Drug Service Providers [Internet]. European Monitoring Centre for Drugs and Drug Addiction. 2020[cited 2020 Nov 28];(1):6. Available from: https://www.emcdda.europa.eu/system/files/publications/12879/emcdda-covid-update-1-25.03.2020v2.pdf
  » https://www.emcdda.europa.eu/system/files/publications/12879/emcdda-covid-update-1-25.03.2020v2.pdf
• ¹⁸
  McCoy KL. Interaction between Cannabinoid System and Toll-Like Receptors Controls Inflammation. Mediators of inflammation. 2016;5831315. https://doi.org/10.1155/2016/5831315
  » https://doi.org/10.1155/2016/5831315
• ¹⁹
  Sexton M, Cudaback E, Abdullah RA, Finnell J, Mischley LK, Rozga M, et al. Cannabis use by individuals with multiple sclerosis: effects on specific immune parameters. Inflammopharmacology. 2014;22(5):295-303. https://doi.org/10.1007/s10787-014-0214-z
  » https://doi.org/10.1007/s10787-014-0214-z
• ²⁰
  Hill KP. Cannabinoids and the Coronavirus. Med Cannabis Cannabinoids. 2020;5(2):118-120. https://doi.org/10.1089/can.2020.0035
  » https://doi.org/10.1089/can.2020.0035
• ²¹
  Khodadadi H, Salles ÉL, Jarrahi A, Chibane F, Costigliola V, Yu JC, et al. Cannabidiol Modulates Cytokine Storm in Acute Respiratory Distress Syndrome Induced by Simulated Viral Infection Using Synthetic RNA. Cannabis Cannabinoid Res. 2020;5(3):197-201. https://doi.org/10.1089/can.2020.0043
  » https://doi.org/10.1089/can.2020.0043
• ²²
  Arksey H, O’Malley L. Scoping studies: Towards a methodological framework. Int J Soc Res Methodol. 2005;8(1):19-32. https://doi.org/10.1080/1364557032000119616
  » https://doi.org/10.1080/1364557032000119616
• ²³
  Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009;6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097
  » https://doi.org/10.1371/journal.pmed.1000097
• ²⁴
  Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation. Ann Intern Med. 2018;169(7):467-73. https://doi.org/10.7326/M18-0850
  » https://doi.org/10.7326/M18-0850
• ²⁵
  Piper C. System for the unified management, assessment, and review of information (SUMARI). J Med Libr Assoc. 2019;107(4):634-636. https://doi.org/10.5195/jmla.2019.790
  » https://doi.org/10.5195/jmla.2019.790
• ²⁶
  Aromataris E, Munn Z (Eds). JBI Manual for Evidence Synthesis. JBI, 2020. https://doi.org/10.46658/JBIMES-20-01
  » https://doi.org/10.46658/JBIMES-20-01
• ²⁷
  Archie SR, Cucullo L. Cerebrovascular and neurological dysfunction under the threat of COVID-19: Is there a comorbid role for smoking and vaping? Int J Mol Sci. 2020;21(11). https://doi.org/10.3390/ijms21113916
  » https://doi.org/10.3390/ijms21113916
• ²⁸
  Costiniuk CT, Jenabian MA. Acute inflammation and pathogenesis of SARS-CoV-2 infection: Cannabidiol as a potential anti-inflammatory treatment? Cytokine Growth Factor Rev. 2020;53:63-65. https://doi.org/10.1016/j.cytogfr.2020.05.008
  » https://doi.org/10.1016/j.cytogfr.2020.05.008
• ²⁹
  Hatoum AS, Morrison CL, Winiger EA, Johnson EC, Agrawal A, Bogdan R. Genetic liability to cannabis use disorder and COVID-19 hospitalization. medRxiv. 2020[cited 2021 Jan 03]. https://doi.org/10.1101/2020.11.15.20229971
  » https://doi.org/10.1101/2020.11.15.20229971
• ³⁰
  Esposito G, Pesce M, Seguella L, Sanseverino W, Lu J, Corpetti C, et al. The potential of cannabidiol in the COVID-19 pandemic. Br J Pharmacol. 2020;177(21):4967-70. https://doi.org/10.1111/bph.15157
  » https://doi.org/10.1111/bph.15157
• ³¹
  Onaivi ES, Sharma V. Cannabis for COVID-19: Can cannabinoids quell the cytokine storm? Future Sci OA. 2020;6(8). https://doi.org/10.2144/fsoa-2020-0124
  » https://doi.org/10.2144/fsoa-2020-0124
• ³²
  Wang B, Kovalchuk A, Li D, Ilnytskyy Y, Kovalchuk I, Kovalchuk O. In search of preventative strategies: novel high-CBD cannabis sativa extracts modulate ACE2 expression in COVID-19 gateway tissues. Aging (Albany NY). 2020;12(22):22425. https://doi.org/10.18632/aging.202225
  » https://doi.org/10.18632/aging.202225
• ³³
  Dzobo K, Chiririwa H, Dandara C, Dzobo W. Coronavirus disease-2019 treatment strategies targeting interleukin-6 signaling and herbal medicine. OMICS. 2020;25(1):13-22. https://doi.org/10.1089/omi.2020.0122
  » https://doi.org/10.1089/omi.2020.0122
• ³⁴
  Rossi F, Tortora C, Argenziano M, di Paola A, Punzo F. Cannabinoid receptor type 2: a possible target in SARS-CoV-2 (CoV-19) infection? Int J Mol Sci. 2020;21(11). https://doi.org/10.3390/ijms21113809
  » https://doi.org/10.3390/ijms21113809
• ³⁵
  Tahamtan A, Tavakoli-Yaraki M, Salimi V. Opioids/cannabinoids as a potential therapeutic approach in COVID-19 patients. Expert Rev Respir Med. 2020;14(10):965-967. https://doi.org/10.1080/17476348.2020.1787836
  » https://doi.org/10.1080/17476348.2020.1787836
• ³⁶
  Land MH, MacNair L, Thomas BF, Peters EN, Bonn-Miller MO. Letter to the editor: possible drug-drug interactions between cannabinoids and candidate COVID-19 drugs. Cannabis Cannabinoid Res. 2020;5(4):340-343. https://doi.org/10.1089/can.2020.0054
  » https://doi.org/10.1089/can.2020.0054
• ³⁷
  Usher K, Bhullar N, Jackson D. Life in the pandemic: Social isolation and mental health. J Clin Nurs. 2020;29(15-16):2756-2757. https://doi.org/10.1111/jocn.15290
  » https://doi.org/10.1111/jocn.15290
• ³⁸
  Rojas-Jara C. Quarantine, forced isolation and substance use. J Neuropsychol. 2020;14(1):24-28. https://doi.org/10.7714/CNPS/14.1.203
  » https://doi.org/10.7714/CNPS/14.1.203
• ³⁹
  Imtiaz S, Wells S, Rehm J, Hamilton HA, Nigatu YT, Wickens CM, et al. Cannabis use during the COVID-19 pandemic in canada : a repeated cross-sectional study. J Addict Med. 2020[cited 2021 Jan 03];00(00):1-7. https://doi.org/10.1097/ADM.0000000000000798
  » https://doi.org/10.1097/ADM.0000000000000798
• ⁴⁰
  Vanderbruggen N, Matthys F, Van Laere S, Zeeuws D, Santermans L, Van den Ameele S, et al. Self-reported alcohol, tobacco, and cannabis use during covid-19 lockdown measures: results from a web-based survey. Eur Addict Res. 2020;26(6):309-315. https://doi.org/10.1159/000510822
  » https://doi.org/10.1159/000510822
• ⁴¹
  Sharma P, Ebbert JO, Rosedahl JK, Philpot LM. Changes in substance use among young adults during a respiratory disease pandemic. SAGE Open Med. 2020;8:205031212096532. https://doi.org/10.1177/2050312120965321
  » https://doi.org/10.1177/2050312120965321
• ⁴²
  Elsohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC. Changes in cannabis potency over the last 2 decades (1995-2014): Analysis of current data in the United States. Biol Psychiatry. 2016;79(7):613-619. https://doi.org/10.1016/j.biopsych.2016.01.004
  » https://doi.org/10.1016/j.biopsych.2016.01.004
• ⁴³
  Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363-374. https://doi.org/10.1038/s41577-020-0311-8
  » https://doi.org/10.1038/s41577-020-0311-8
• ⁴⁴
  Pascale A. Psychoactive substance use during the COVID-19 pandemic: toxicological implications from a comprehensive approach and therapeutic challenges. Rev Méd. Urug [Internet]. 2020 [cited 2020 Nov 28];36(3):247-251. Available from: http://www.scielo.edu.uy/pdf/rmu/v36n3/1688-0390-rmu-36-03-247.pdf
  » http://www.scielo.edu.uy/pdf/rmu/v36n3/1688-0390-rmu-36-03-247.pdf
• ⁴⁵
  Rezkalla S, Kloner RA. Cardiovascular effects of marijuana. Trends Cardiovasc Med. 2019;29(7):403-407. https://doi.org/10.1016/j.tcm.2018.11.004
  » https://doi.org/10.1016/j.tcm.2018.11.004
• ⁴⁶
  Pillai P, Joseph JP, Fadzillah NHM, Mahmod M. COVID-19 and Major Organ Thromboembolism: Manifestations in Neurovascular and Cardiovascular Systems. J Stroke Cerebrovasc Dis. 2021;30(1):105427. https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.105427
  » https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.105427
• ⁴⁷
  Vidot DC, Islam JY, Marlene Camacho-Rivera, Harrell MB, Rao DR, Chavez JV, Lucas G Ochoa, et al. The COVID-19 cannabis health study: Results from an epidemiologic assessment of adults who use cannabis for medicinal reasons in the United States. J Addict Dis. 2020 [cited 2021 Jan 03];15:1-11. https://doi.org/10.1080/10550887.2020.1811455
  » https://doi.org/10.1080/10550887.2020.1811455
• ⁴⁸
  World Drug Report 2020. Drug use and health consequences [Internet]. 2020 [cited 2021 Jun 28];2: E.20.XI.6. Available from: https://www.unodc.org/unodc/en/data-and-analysis/wdr-2021_booklet-2.html
  » https://www.unodc.org/unodc/en/data-and-analysis/wdr-2021_booklet-2.html
• ⁴⁹
  Gonçalves AMS, Ferreira PS, Abreu ÂMM, Pillon SC, Jezus SV. Screening and brief interventions strategies as possibilities for preventive nurses’ practice. Rev Eletr Enf. 2011;13(2):355-360. https://doi.org/10.5216/ree.v13i2.10502
  » https://doi.org/10.5216/ree.v13i2.10502
• ⁵⁰
  Anderson P, Kłoda K, Kaner E, Reynolds J, Bendtsen P, Pelgrum-Keurhorst MN, et al. Impact of practice, provider and patient characteristics on delivering screening and brief advice for heavy drinking in primary healthcare: Secondary analyses of data from the ODHIN five-country cluster randomized factorial trial. Eur J Gen Pract. 2017;23(1):241-5. https://doi.org/10.1080/13814788.2017.1374365
  » https://doi.org/10.1080/13814788.2017.1374365
• ⁵¹
  Pacher P, Steffens S, Haskó G, Schindler TH, Kunos G. Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly. Nat Rev Cardiol. 2017;15. https://doi.org/10.1038/nrcardio.2017.130
  » https://doi.org/10.1038/nrcardio.2017.130
• ⁵²
  Mamber SW, Krakowka S, Osborn J, Saberski L, Rhodes RG, Dahlberg AE, et al. Can Unconventional Immunomodulatory Agents Help Alleviate COVID-19 Symptoms and Severity? mSphere. 2020;5(3). https://doi.org/10.1128/msphere.00288-20
  » https://doi.org/10.1128/msphere.00288-20
• ⁵³
  Thibaut F, Hoehe MR. Cannabinoids: For better and for worse. Dialogues Clin Neurosci. 2020;22(3):201-204. https://doi.org/10.31887/DCNS.2020.22.3/FTHIBAUT
  » https://doi.org/10.31887/DCNS.2020.22.3/FTHIBAUT

Edited by

EDITOR IN CHIEF: Dulce Barbosa

ASSOCIATE EDITOR: Rafael Silva

Publication Dates

• Publication in this collection
  07 Mar 2022
• Date of issue
  2022

History

• Received
  14 Jan 2021
• Accepted
  01 Sept 2021